Shan Yi, Ma Yang, Chen Hanfei, Zhao Sichao, Shi Mingzhu, Bai Min, Hu Junrui
College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, People's Republic of China.
Key Laboratory of Ningxia Ethnomedicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, 750004, People's Republic of China.
J Inflamm Res. 2025 Aug 31;18:11979-11998. doi: 10.2147/JIR.S532156. eCollection 2025.
Precancerous lesions of gastric cancer (PLGC) represent a crucial juncture in the transformation from gastritis to gastric cancer. Qijie Xiaopi Decoction (QJXPD), a Chinese herbal medicine formulation that has been applied in clinical practice to manage PLGC, which is capable of effectively relieving the symptoms experienced by patients such conditions. However, its mechanism of action remains unclear. The aim of this study is to elucidate the mechanism of action of QJXPD in the treatment of PLGC.
Ultra-high-performance liquid chromatography coupled with hybrid quadrupole-orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS) was employed to pinpoint the chemical components of QJXPD. On this basis, network pharmacology and molecular docking were employed to pinpoint the main ingredients, probable targets, and associated pathways of QJXPD in treating of PLGC. A PLGC rat model was replicated using a compound modeling method mainly based on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), to observe the therapeutic effects of QJXPD on PLGC.
The undiluted QJXPD solution contained 1069 compounds. Network pharmacology analysis revealed that QJXPD's anti-PLGC effects involved 119 active ingredients and 332 potential targets, primarily enriched in the PI3K/AKT pathway. Protein-protein interaction (PPI) analysis suggested that TP53, AKT1, SRC, STAT3, and EGFR were the key targets. Through molecular docking, it was discovered that the core targets exhibited a strong binding affinity with the primary active ingredients. Animal experiments have verified that QJXPD can significantly improve the general condition in PLGC rats, increase body weight, repair the damaged gastric mucosa and diminish the inflammatory infiltration, induce apoptosis of gastric mucosal cells, upregulate the expression of LC3, Beclin-1, and Bax and downregulate the expression of p62 and Bcl-2. The PI3K/AKT/mTOR pathway was inhibited by QJXPD.
QJXPD effectively alleviated the pathological injury of gastric mucosa in PLGC rats by inhibiting the PI3K/AKT/mTOR signaling pathway and inducing cellular autophagy and apoptosis.
胃癌癌前病变(PLGC)是胃炎向胃癌转变的关键节点。启膈消痞汤(QJXPD)是一种已应用于临床治疗PLGC的中药方剂,能够有效缓解此类病症患者的症状。然而,其作用机制尚不清楚。本研究旨在阐明QJXPD治疗PLGC的作用机制。
采用超高效液相色谱-四极杆/静电场轨道阱串联质谱联用技术(UHPLC-Q-Exactive Orbitrap-MS)确定QJXPD的化学成分。在此基础上,运用网络药理学和分子对接技术确定QJXPD治疗PLGC的主要成分、可能的靶点及相关通路。采用主要基于N-甲基-N'-硝基-N-亚硝基胍(MNNG)的复合建模方法复制PLGC大鼠模型,观察QJXPD对PLGC的治疗效果。
QJXPD原液含有1069种化合物。网络药理学分析显示,QJXPD的抗PLGC作用涉及119种活性成分和332个潜在靶点,主要富集于PI3K/AKT通路。蛋白质-蛋白质相互作用(PPI)分析表明,TP53、AKT1、SRC、STAT3和EGFR是关键靶点。通过分子对接发现,核心靶点与主要活性成分表现出较强的结合亲和力。动物实验证实,QJXPD可显著改善PLGC大鼠的一般状况,增加体重,修复受损胃黏膜,减少炎症浸润,诱导胃黏膜细胞凋亡,上调LC3、Beclin-1和Bax的表达,下调p62和Bcl-2的表达。QJXPD抑制了PI3K/AKT/mTOR通路。
QJXPD通过抑制PI3K/AKT/mTOR信号通路,诱导细胞自噬和凋亡,有效减轻了PLGC大鼠胃黏膜的病理损伤。